

(FILE 'HOME' ENTERED AT 17:24:35 ON 08 OCT 2000)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, CANCERLIT, SCISEARCH, TOXLINE,  
CAOLD, AIPAT, AIPAT2, CROPU, DGENE, DPCI, EUROPATFULL, IFIPAT,  
INPADOC,  
JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE, PATOSEP, PATOSWO, PCTFULL,  
PIRA, RAPRA, TULSA, TULSA2, USPATFULL, ...' ENTERED AT 17:24:54 ON 08

OCT

2000

L1 601654 S GLYCOPROTEIN OR CONJUGATE  
L2 1364464 S MANNOSE OR GALACTOSE OR N-ACETLYGLUCOSAMINE OR  
N-ACETYLLACTOS  
L3 14682 S L1 (30A) L2  
L4 35854 S PRODRUG  
L5 9 S L3 (30A) L4  
L6 6 DUP REM L5 (3 DUPLICATES REMOVED)  
L7 5979823 S TUMOR OR CANCER OR MALIGNAN#### OR TUMOUR OR NEOPLAS###  
L8 557 S L7 (30A) L3  
L9 2963340 S ENZYME OR ENZYMATIC  
L10 52 S L8 (30A) L9  
L11 31 DUP REM L10 (21 DUPLICATES REMOVED)  
L12 2828955 S ANTIBOD### OR FUSION GLYCOPROTEIN OR CONJUGATE  
L13 52 S L1 (30A) L2 (30A)L7 (30A) L9  
L14 31 DUP REM L13 (21 DUPLICATES REMOVED)

L6 ANSWER 2 OF 6 USPATFULL  
AN 1998:61623 USPATFULL  
TI Method and compositions for treating malignant tumors and inhibiting  
metastases of malignant tumors  
IN Rubin, David, San Diego, CA, United States  
PA CO Enzyme Technology Ltd., San Diego, CA, United States (U.S.  
corporation)  
PI US 5760008 19980602  
AI US 1996-666643 19960618 (8)  
RLI Continuation-in-part of Ser. No. US 1994-360352, filed on 21 Dec 1994,  
now patented, Pat. No. US 5639737 which is a continuation-in-part of  
Ser. No. US 1993-138195, filed on 20 Oct 1993, now patented, Pat. No.  
US  
5476842 which is a continuation-in-part of Ser. No. US 1991-787347,  
filed on 4 Nov 1991, now abandoned And a continuation-in-part of Ser.  
No. US 1993-57666, filed on 5 May 1993, now patented, Pat. No. US  
5340803  
DT Utility  
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Lee, Howard C.  
LREP Browdy and Neimark  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1248  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
DETD . . . this specification, can be achieved by administering glucose  
to  
the patient thirty minutes prior to the treatment, as orally  
administered **glucose** expresses itself in acidification of the  
tumor due to accumulation of lactic acid. Of course, if the  
**prodrug conjugate** used is a **glucose**  
**conjugate**, an acidification compound other than **glucose**

	Type	L #	Hits	Search Text	Dbs	Time Stamp	Comments	Error Definition	Err ors
1	BRS	L1	33286	glycoprotein or conjugate	USPAT	2000/10/08 17:15			0
2	BRS	L2	61701	mannose or galactose or N-acetylglucosamine or n-acetylactose or glucose or fucose	USPAT	2000/10/08 17:16			0
3	BRS	L3	651	1 near30 2	USPAT	2000/10/08 17:17			0
4	BRS	L4	3191	prodrug	USPAT	2000/10/08 17:17			0
5	BRS	L5	3	3 near50 4	USPAT	2000/10/08 17:17			0
6	BRS	L6	51189	tumor or cancer or malignant\$4 or tumour neoplas\$3	USPAT	2000/10/08 17:18			0
7	BRS	L7	21	3 near50 6	USPAT	2000/10/08 17:18			0